Fulgent Genetics (FLGT) Short-term Investments (2016 - 2026)

Fulgent Genetics has disclosed Short-term Investments across 11 years of filings, most recently posting $252.9 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $252.9 million, changed 0.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $252.9 million (changed 0.05% YoY), and the FY2025 annual result was $285.9 million, up 40.86% from the prior year.
• Short-term Investments came in at $252.9 million for Q1 2026 at Fulgent Genetics, down from $285.9 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $446.7 million in Q4 2022 to a low of $155.0 million in Q3 2024.
• The 5-year median for Short-term Investments is $258.2 million (2025), against an average of $301.0 million.
• Across the five-year window, Short-term Investments jumped 88.89% in 2023 and slumped 59.6% in 2024, its largest moves.
• Fulgent Genetics' Short-term Investments stood at $446.7 million in 2022, then decreased by 26.87% to $326.7 million in 2023, then sank by 37.87% to $203.0 million in 2024, then jumped by 40.86% to $285.9 million in 2025, then declined by 11.54% to $252.9 million in 2026.
• The last three Short-term Investments figures came in at $252.9 million (Q1 2026), $285.9 million (Q4 2025), and $258.2 million (Q3 2025), per Business Quant data.